top of page
Figure 1.TIF

Diseases caused by pathogenic microorganisms including bacteria and viruses can cause serious medical issues including death and result in huge economic losses. Despite the myriad of recent advances in the rapid and accurate detection of pathogens, large volume clinical samples with a low concentration of pathogens continue to present challenges for diagnosis and surveillance. We here report a simple and label-free approach via homobifunctional imidoesters (HIs) with a microfluidic platform (SLIM) to efficiently enrich and extract pa- thogens at low concentrations from clinical samples. The SLIM system consists of an assembled double micro- fluidic chip for streamlining large volume processing and HIs for capturing pathogens and isolating nucleic acids by both electrostatic and covalent interaction without a chaotropic detergent or bulky instruments. The SLIM system significantly increases the enrichment and extraction rate of pathogens (up to 80% at 10 CFU (colony forming unit) in a 1 mL volume within 50 min). We demonstrated its clinical utility in large sample volumes from 46 clinical specimens including environmental swabs, saliva, and blood plasma. The SLIM system showed higher sensitivity with these samples and could detect pathogens that were below the threshold of detection with other methods. Finally, by combining our SLIM approach with an isothermal optical sensor, pathogens could be de- tected at a very high sensitivity in blood plasma samples within 80 min via enrichment, extraction and detection steps. Our SLIM system thus provides a simple, reliable, cost-effective and ultrasensitive pathogen diagnosis platform for use with large volume clinical samples and would thus have significant utility for various infectious diseases.

Figure 3.TIF

Cell-free nucleic acids (cfNAs) are emerging diagnostic biomarkers for monitoring the treatment and recurrence of cancers. In particular, the biological role and clinical usefulness of cfNAs obtained from the plasma
of patients with various cancers are popular and still intensely explored,
yet most studies are limited by technical problems during cfNA isolation.
A dimethyl dithiobispropionimidate (DTBP)-based microchannel platform that enables spontaneous cfNA capture in 15 min with minimal cellular background and no requirements for use of bulky instruments is reported first. This platform identified KRAS and BRAF hot-spot mutations following cfDNA isolation from the blood plasma and tissues obtained from 30 colorectal cancer patients. The correlation of mutations between the primary tissues and plasma from the patients was high using this platform with whole genome sequencing compared to the spin-column method. This platform can also be combined with various detection approaches (biooptical sensor, Sanger sequencing, and polymerase chain reaction (PCR)) for rapid, simple, low-cost, and sensitive circulating tumor DNA detection in blood plasma. The efficiency and versatility of this platform in isolating cfNAs from liquid biopsies has applications in cancer treatment and precision medicine.

Figure 1.png

A total of 152 patients were enrolled between January 2018 and January 2019. The mean±SD age was 59.6±16.0 years, and 104 patients (68.4%) were male. Only three (2%) of the 152 patients had HIV infection. 60 patients were diagnosed with TB, 18 with smear-positive culture-positive TB, 19 with smear-negative culture-positive TB, and 23 with smear-negative culture-negative clinical TB. The remaining 92 patients had diseases other than TB. A comparison of the diagnostic performances of Xpert MTB/RIF and SLIM assays based on clinical diagnosis and stratified by M. tuberculosis culture results, are presented in table 1. In patients, the sensitivity for detecting TB by Xpert MTB/RIF, SLIM 1 mL, and SLIM 2 mL assays were 37% (95% CI 25–50%), 60% (95% CI 47–72%) and 84% (95% CI 71–92%), respectively. SLIM 1 mL and SLIM 2 mL sensitivities were significantly higher than Xpert MTB/RIF ( p=0.001 and p<0.001, respectively). The specificity of Xpert MTB/RIF, SLIM 1 mL, and SLIM 2 mL were 100% (95% CI 96–100%), 91% (95% CI 84–96%) and 87% (95% CI 76–94%), respectively.

슬라이드1.TIF

Rapid identification of emerging infectious pathogens is crucial for preventing public health threats. Various pathogen detection techniques have been introduced; however, most techniques are time-consuming and lack multiple-target detection specificity. Although multiple-target detection techniques can distinguish emerging infectious pathogens from related pathogens, direct amplification methods have not been widely examined. Here, we present a novel arch-shaped multiple-target sensor capable of rapid pathogen identification using direct amplification in clinical samples. In this study, an arch-shaped amplification containing primer sequences was designed to rapidly amplify multiple targets. Further, the sensing platform allowed for sensitive and specific detection of human coronavirus, Middle East respiratory syndrome, Zika virus, and Ebola virus down to several copies. This platform also simultaneously distinguished between Middle East respiratory syndrome and human coronavirus in clinical specimens within 20 min. This arch-shaped multiple-target sensing assay can provide rapid, sensitive, and accurate diagnoses of emerging infectious diseases in clinical applications.

bottom of page